A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

This study is testing a new combination of drugs — including an anti-CD19 antibody, rituximab, gemcitabine, oxaliplatin, and methotrexate (called A-RGEMOX) — for people with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that came back or did not respond within 12 months of first treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with DLBCL or a related high-grade B-cell lymphoma, confirmed by tissue biopsy - Your cancer either relapsed within 12 months of completing first-line treatment or did not respond to first-line therapy - You have at least one measurable tumor on imaging - You have not had CAR-T cell therapy previously **You may NOT be eligible if...** - Your cancer has spread to the brain or spinal fluid - You have serious heart, liver, or kidney problems - You have an active serious infection - You are pregnant or breastfeeding - You have had prior CAR-T therapy Talk to your doctor to see if this trial is right for you.